BD, Accelerate to Collaborate on Testing-Kit Distribution

By Connor Hart

Becton, Dickinson & Co. and Accelerate Diagnostics Inc. on Monday said the companies would collaborate to bring rapid antimicrobial identification and susceptibility to more clinicians and patients worldwide.

In the collaboration, BD, a Franklin Lakes, N.J.-based medical technology company, would market and sell Accelerate Diagnostics' testing kits through its global sales network.

Accelerate, a Tucson, Ariz.-based company, offers rapid testing solutions for antibiotic resistance and susceptibility, providing results in hours as opposed to one to two days with some traditional laboratory methods, the company said.

BD would market and sell two of Accelerate's proprietary testing kits, one of which is the first test cleared by the U.S. Food and Drug Administration to deliver both rapid identification and phenotypic antibiotic susceptibility results in hours direct from positive blood cultures, the companies said.

"Through our collaboration with Accelerate Diagnostics, we can help clinicians more quickly, efficiently and effectively treat patients, which may lead to a reduction in health care costs and help slow the spread of antimicrobial resistance," said Brooke Story, president of Integrated Diagnostic Solutions for BD.

Shares of Accelerate rose more than 15% in premarket trading on Monday, while shares of BD remained steady.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

August 15, 2022 07:57 ET (11:57 GMT)

Becton Dickinson (NYSE:BDX)
Historical Stock Chart
From Mar 2024 to Apr 2024